Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Literature DB >> 22821764

Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Abstract

The results of recent clinical trials for the management of limited-stage Hodgkin lymphoma have led to considerable debate, especially regarding the role of radiation therapy. This review highlights those recent trials and provides perspectives regarding their interpretation from a radiation oncologist and a hematologist. The trial protocol is available at http://www.nejm.org/doi/suppl/10.1056/NEJMoa1111961/suppl_file/nejmoa1111961_protocol.pdf.

Entities: Disease

Mesh：

Year: 2012 PMID： 22821764 PMCID： PMC3512228 DOI： 10.1182/blood-2012-05-423236

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

52 in total

1. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study.

Authors: Agnes Dechartres; Isabelle Boutron; Ludovic Trinquart; Pierre Charles; Philippe Ravaud
Journal: Ann Intern Med Date: 2011-07-05 Impact factor: 25.391

2. Hodgkin lymphoma.

Authors: Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Celeste M Bello; Philip J Bierman; Kristie A Blum; Bouthaina Dabaja; Ysabel Duron; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; David G Maloney; David Mansur; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Matthew Poppe; Barbara Pro; Lawrence Weiss; Jane N Winter; Joachim Yahalom
Journal: J Natl Compr Canc Netw Date: 2011-09-01 Impact factor: 11.908

3. Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors: V T Devita; A A Serpick; P P Carbone
Journal: Ann Intern Med Date: 1970-12 Impact factor: 25.391

4. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease.

Authors: R Zittoun; A Audebert; B Hoerni; A Bernadou; M Krulik; J Rojouan; H Eghbali; H Merle-Béral; Y Parlier; J Diebold
Journal: J Clin Oncol Date: 1985-02 Impact factor: 44.544

5. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Authors: Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert
Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544

6. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?

Authors: S Laskar; T Gupta; S Vimal; M A Muckaden; T K Saikia; S K Pai; K N Naresh; K A Dinshaw
Journal: J Clin Oncol Date: 2003-12-02 Impact factor: 44.544

7. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.

Authors: Bhishamjit S Chera; Christina Rodriguez; Christopher G Morris; Debbie Louis; Daniel Yeung; Zuofeng Li; Nancy P Mendenhall
Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-20 Impact factor: 7.038

Review 8. Late effects of Hodgkin's disease and its treatment.

Authors: Andrea K Ng; Peter M Mauch
Journal: Cancer J Date: 2009 Mar-Apr Impact factor: 3.360

9. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study.

Authors: G P Biti; G Cimino; C Cartoni; S M Magrini; A P Anselmo; R M Enrici; G P Bellesi; A Bosi; G Papa; D Giannarelli
Journal: J Clin Oncol Date: 1992-03 Impact factor: 44.544

10. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial.

Authors: R H Advani; R T Hoppe; D Baer; J Mason; R Warnke; J Allen; S Daadi; S A Rosenberg; S J Horning
Journal: Ann Oncol Date: 2012-11-07 Impact factor: 32.976

8 in total

Review 1. The evolving role of response-adapted PET imaging in Hodgkin lymphoma.

Authors: Michael Coyle; Lale Kostakoglu; Andrew M Evens
Journal: Ther Adv Hematol Date: 2016-04

Review 2. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant.

Authors: Eric Van Den Neste; Olivier Casasnovas; Marc André; Mohamed Touati; Delphine Senecal; Véronique Edeline; Aspasia Stamatoullas; Luc Fornecker; Bénédicte Deau; Thomas Gastinne; Oumédaly Reman; Isabelle Gaillard; Cécile Borel; Pauline Brice; Christophe Fermé
Journal: Haematologica Date: 2013-08 Impact factor: 9.941

Review 3. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Authors: Andrew M Evens; Lale Kostakoglu
Journal: Blood Date: 2014-11-27 Impact factor: 22.113

Review 4. Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.

Authors: Annette E Hay; Ralph M Meyer
Journal: Hematol Oncol Clin North Am Date: 2014-02 Impact factor: 3.722